ATTO
Earnings company data as of 4:50 AM ET 10/23
- 0 of 1 EPS beats
History
2 periods, newest first. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 2 Dec | EPS | — | — | — |
| Rev | — | — | — | ||
| FY2026 Q2 | 2 Sep | EPS | -4.62 | -4.88 | Miss |
| Rev | — | $500.0K | — |
Insider trades
Open-market buys and sales by ATTO's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $52.4M bought by 6 insiders
- $4.5M sold by 2 insiders outside a trading plan
- None no planned (10b5-1) sales
-
Colin Walsh DirectorBuy$10.3M 585,000 shares at $17.58 +24% to stakeTraded Aug 5–6 Filed Aug 28
-
Colin Walsh DirectorSale$2.3M 105,807 shares at $21.28 100% of stakeTraded Aug 5 Filed Aug 28
-
venBio Global Strategic Fund IV, L.P. 10% ownerBuy$6.5M 382,352 shares at $17.00 +10% to stakeTraded Aug 6 Filed Aug 10
-
Sanofi 10% ownerBuy$5.1M 300,000 shares at $17.00 +38% to stakeTraded Aug 6 Filed Aug 7
-
Redmile Group, LLC 10% owner, +2 joint filersBuy$10.2M 600,000 shares at $17.00Traded Aug 6 Filed Aug 7
-
Frazier Life Sciences XI, L.P. 10% owner, +2 joint filersBuy$10M 588,235 shares at $17.00 +11% to stakeTraded Aug 6 Filed Aug 6
Also filed in the last 12 months, not counted as buying or selling: 14 conversions.
SEC filings
Recent issuer filings from EDGAR, 9 shown.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.